Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther June 1 2013 12 (6) 829-829;

Reviews

  • Reviews
    Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
    Lisa Vincenz, Richard Jäger, Michael O'Dwyer and Afshin Samali
    Mol Cancer Ther June 1 2013 12 (6) 831-843; DOI:10.1158/1535-7163.MCT-12-0782

  • Reviews
    Cyclooxygenase-2, Epidermal Growth Factor Receptor, and Aromatase Signaling in Inflammation and Mesothelioma
    Barbara Nuvoli and Rossella Galati
    Mol Cancer Ther June 1 2013 12 (6) 844-852; DOI:10.1158/1535-7163.MCT-12-1103

Chemical Therapeutics

  • Chemical Therapeutics | AuthorChoice
    Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
    Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother and Lisa D. Belmont
    Mol Cancer Ther June 1 2013 12 (6) 853-864; DOI:10.1158/1535-7163.MCT-12-0949

  • Chemical Therapeutics
    RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
    Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim and Yung-Jue Bang
    Mol Cancer Ther June 1 2013 12 (6) 865-877; DOI:10.1158/1535-7163.MCT-12-0950

  • Chemical Therapeutics
    The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
    Yun Dai, Shuang Chen, Maciej Kmieciak, Liang Zhou, Hui Lin, Xin-Yan Pei and Steven Grant
    Mol Cancer Ther June 1 2013 12 (6) 878-889; DOI:10.1158/1535-7163.MCT-12-0902

  • Chemical Therapeutics
    The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
    Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett and Dennis J. Slamon
    Mol Cancer Ther June 1 2013 12 (6) 890-900; DOI:10.1158/1535-7163.MCT-12-0998

  • Chemical Therapeutics
    Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
    H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen and Keiran S.M. Smalley
    Mol Cancer Ther June 1 2013 12 (6) 901-912; DOI:10.1158/1535-7163.MCT-12-1003

  • Chemical Therapeutics
    A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
    Yoshiko Awazu, Kazuhide Nakamura, Akio Mizutani, Yuichi Kakoi, Hidehisa Iwata, Seiji Yamasaki, Naoki Miyamoto, Shinichi Imamura, Hiroshi Miki and Akira Hori
    Mol Cancer Ther June 1 2013 12 (6) 913-924; DOI:10.1158/1535-7163.MCT-12-1011

  • Chemical Therapeutics | AuthorChoice
    Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
    Jing Wang, Natalie W. Pursell, Maria Elena S. Samson, Ruzanna Atoyan, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner and Cheng-Jung Lai
    Mol Cancer Ther June 1 2013 12 (6) 925-936; DOI:10.1158/1535-7163.MCT-12-1045

  • Chemical Therapeutics
    Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
    Shili Xu, Fedora Grande, Antonio Garofalo and Nouri Neamati
    Mol Cancer Ther June 1 2013 12 (6) 937-949; DOI:10.1158/1535-7163.MCT-12-1082

  • Chemical Therapeutics
    Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
    Hua Xie, Mee-Hyun Lee, Feng Zhu, Kanamata Reddy, Zunnan Huang, Dong Joon Kim, Yan Li, Cong Peng, Do Young Lim, Soouk Kang, Sung Keun Jung, Xiang Li, Haitao Li, Weiya Ma, Ronald A. Lubet, Jian Ding, Ann M. Bode and Zigang Dong
    Mol Cancer Ther June 1 2013 12 (6) 950-958; DOI:10.1158/1535-7163.MCT-12-1241

  • Chemical Therapeutics
    Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
    Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell and Nicola J. Curtin
    Mol Cancer Ther June 1 2013 12 (6) 959-967; DOI:10.1158/1535-7163.MCT-12-0707

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
    Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold and David M. Goldenberg
    Mol Cancer Ther June 1 2013 12 (6) 968-978; DOI:10.1158/1535-7163.MCT-12-1170

  • Large Molecule Therapeutics | Free Article
    Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu
    Yu Cao, Khalid A. Mohamedali, John W. Marks, Lawrence H. Cheung, Walter N. Hittelman and Michael G. Rosenblum
    Mol Cancer Ther June 1 2013 12 (6) 979-991; DOI:10.1158/1535-7163.MCT-13-0002

Cancer Therapeutics Insights

  • Cancer Therapeutics Insights
    BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
    Bercin Kutluk Cenik, Katherine T. Ostapoff, David E. Gerber and Rolf A. Brekken
    Mol Cancer Ther June 1 2013 12 (6) 992-1001; DOI:10.1158/1535-7163.MCT-12-0995

  • Cancer Therapeutics Insights
    Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
    Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, Boris Winterhoff, Siân Jones, Victor E. Velculescu, Natarajan Venkatesan, Hong-Mei Rong, Sugandha Dandekar, Nitin Udar, Fritz Jänicke, Gerrit Los, Dennis J. Slamon and Gottfried E. Konecny
    Mol Cancer Ther June 1 2013 12 (6) 1002-1015; DOI:10.1158/1535-7163.MCT-12-0813

  • Cancer Therapeutics Insights | AuthorChoice
    Downregulation of Hepatoma-Derived Growth Factor Contributes to Retarded Lung Metastasis via Inhibition of Epithelial–Mesenchymal Transition by Systemic POMC Gene Delivery in Melanoma
    Han-En Tsai, Guei-Sheung Liu, Mei-Lang Kung, Li-Feng Liu, Jian-Ching Wu, Chia-Hua Tang, Ching-Hui Huang, San-Cher Chen, Hing-Chung Lam, Chieh-Shan Wu and Ming-Hong Tai
    Mol Cancer Ther June 1 2013 12 (6) 1016-1025; DOI:10.1158/1535-7163.MCT-12-0832

  • Cancer Therapeutics Insights
    Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
    Xiaohai Wang, Soo Ok Lee, Shujie Xia, Qi Jiang, Jie Luo, Lei Li, Shuyuan Yeh and Chawnshang Chang
    Mol Cancer Ther June 1 2013 12 (6) 1026-1037; DOI:10.1158/1535-7163.MCT-12-0895

  • Cancer Therapeutics Insights
    Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis
    Dongsheng Gu, Hailan Liu, Gloria H. Su, Xiaoli Zhang, Helen Chin-Sinex, Helmut Hanenberg, Marc S. Mendonca, Harlan E. Shannon, E. Gabriela Chiorean and Jingwu Xie
    Mol Cancer Ther June 1 2013 12 (6) 1038-1048; DOI:10.1158/1535-7163.MCT-12-1030

  • Cancer Therapeutics Insights
    Hrk Mediates 2-Methoxyestradiol–Induced Mitochondrial Apoptotic Signaling in Prostate Cancer Cells
    Inik Chang, Shahana Majid, Sharanjot Saini, Mohd S. Zaman, Soichiro Yamamura, Takeshi Chiyomaru, Varahram Shahryari, Shinichiro Fukuhara, Guoren Deng, Rajvir Dahiya and Yuichiro Tanaka
    Mol Cancer Ther June 1 2013 12 (6) 1049-1059; DOI:10.1158/1535-7163.MCT-12-1187

  • Cancer Therapeutics Insights
    SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
    Monica Brenca, Sabrina Rossi, Erica Lorenzetto, Elena Piccinin, Sara Piccinin, Francesca Maria Rossi, Alberto Giuliano, Angelo Paolo Dei Tos, Roberta Maestro and Piergiorgio Modena
    Mol Cancer Ther June 1 2013 12 (6) 1060-1072; DOI:10.1158/1535-7163.MCT-13-0005

  • Cancer Therapeutics Insights
    Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair
    Kushtrim Kryeziu, Ute Jungwirth, Mir Alireza Hoda, Franziska Ferk, Siegfried Knasmüller, Claudia Karnthaler-Benbakka, Christian R. Kowol, Walter Berger and Petra Heffeter
    Mol Cancer Ther June 1 2013 12 (6) 1073-1084; DOI:10.1158/1535-7163.MCT-13-0065

  • Cancer Therapeutics Insights
    Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
    Stefania Stella, Elena Tirrò, Enrico Conte, Fabio Stagno, Francesco Di Raimondo, Livia Manzella and Paolo Vigneri
    Mol Cancer Ther June 1 2013 12 (6) 1085-1098; DOI:10.1158/1535-7163.MCT-12-0550

  • Cancer Therapeutics Insights
    Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP
    Xuemei Xie, Chandra Bartholomeusz, Ahmed A. Ahmed, Anna Kazansky, Lixia Diao, Keith A. Baggerly, Gabriel N. Hortobagyi and Naoto T. Ueno
    Mol Cancer Ther June 1 2013 12 (6) 1099-1111; DOI:10.1158/1535-7163.MCT-12-0737

Companion Diagnostics & Cancer Biomarkers

  • Companion Diagnostics & Cancer Biomarkers
    Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
    Lai-Ping Zhong, Dong-Wang Zhu, William N. William Jr, Ying Liu, Jie Ma, Cheng-Zhe Yang, Xiao Yang, Li-Zhen Wang, Jiang Li, Jeffrey N. Myers, J. Jack Lee, Chen-Ping Zhang and Zhi-Yuan Zhang
    Mol Cancer Ther June 1 2013 12 (6) 1112-1121; DOI:10.1158/1535-7163.MCT-12-1013

  • Companion Diagnostics & Cancer Biomarkers
    HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
    Elicia Penuel, Congfen Li, Vaishali Parab, Luciana Burton, Kyra J. Cowan, Mark Merchant, Robert L. Yauch, Premal Patel, Amy Peterson, Garret M. Hampton, Mark R. Lackner and Priti S. Hegde
    Mol Cancer Ther June 1 2013 12 (6) 1122-1130; DOI:10.1158/1535-7163.MCT-13-0015

  • Companion Diagnostics & Cancer Biomarkers
    ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer
    Rebekah L. Zinn, Eric E. Gardner, Luigi Marchionni, Sara C. Murphy, Irina Dobromilskaya, Christine L. Hann and Charles M. Rudin
    Mol Cancer Ther June 1 2013 12 (6) 1131-1139; DOI:10.1158/1535-7163.MCT-12-0618

Tools and Technologies

  • Tools and Technologies
    Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
    Holly A.F. Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers and Brian G. Van Ness
    Mol Cancer Ther June 1 2013 12 (6) 1140-1150; DOI:10.1158/1535-7163.MCT-12-1151

Back to top
PreviousNext
Molecular Cancer Therapeutics: 12 (6)
June 2013
Volume 12, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu
  • Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
  • Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
  • BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

Jump to

  • Highlights
  • Reviews
  • Chemical Therapeutics
  • Large Molecule Therapeutics
  • Cancer Therapeutics Insights
  • Companion Diagnostics & Cancer Biomarkers
  • Tools and Technologies
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement